BioSpace News Archive

ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.

RespirAI Medical, a digital startup company based in Israel, has announced it has entered into a collaboration with Mayo Clinic for developing a wearable AI-based home monitoring platform for respiratory diseases.

As we mark Breast Cancer Awareness Month in October, doctors at ProCure Proton Therapy Center are raising awareness about the link between dense breasts and breast cancer.

Regeneron Pharmaceuticals, Inc. announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology, engineering and mathematics ecosystem through high-quality, equitable engagement programs for students and science teachers.

MiRus® announced that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe® plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market.

Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, today announced an agreement to be acquired by Eli Lilly and Company (“Lilly”).

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.

Adial Pharmaceuticals, Inc. announced that it has been awarded the 2023 Best Practices Technology Innovation Leadership Award in the North American precision medicine for addiction disorders industry by Frost & Sullivan, an American business consulting firm that offers market research and analysis, growth strategy consulting, and corporate training.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that a late-breaking presentation highlighting results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Boston, MA (November 10th – 14th).

ReWalk Robotics Ltd. today announced that ReWalk will be presenting the ReWalk Exoskeleton to the GITEX GLOBAL audience in Dubai this week from Oct 16-20, 2023.